Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia cepacia 30S ribosomal protein S16 (rpsP) CSB-YP453698BXS
CSB-EP453698BXS
CSB-BP453698BXS
CSB-MP453698BXS
CSB-EP453698BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia UPF0042 nucleotide-binding protein BceJ2315_08000 (BceJ2315_08000) CSB-YP453699BXS
CSB-EP453699BXS
CSB-BP453699BXS
CSB-MP453699BXS
CSB-EP453699BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia 3-phosphoshikimate 1-carboxyvinyltransferase (aroA) CSB-YP453700BXS
CSB-EP453700BXS
CSB-BP453700BXS
CSB-MP453700BXS
CSB-EP453700BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Protein FdhD homolog (fdhD) CSB-YP453701BXS
CSB-EP453701BXS
CSB-BP453701BXS
CSB-MP453701BXS
CSB-EP453701BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Trigger factor (tig) CSB-YP453702BXS
CSB-EP453702BXS
CSB-BP453702BXS
CSB-MP453702BXS
CSB-EP453702BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia N utilization substance protein B homolog (nusB) CSB-YP453703BXS
CSB-EP453703BXS
CSB-BP453703BXS
CSB-MP453703BXS
CSB-EP453703BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Putative phosphotransferase BceJ2315_20370 (BceJ2315_20370) CSB-YP453704BXS
CSB-EP453704BXS
CSB-BP453704BXS
CSB-MP453704BXS
CSB-EP453704BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia 30S ribosomal protein S2 (rpsB) CSB-YP453705BXS
CSB-EP453705BXS
CSB-BP453705BXS
CSB-MP453705BXS
CSB-EP453705BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia UPF0301 protein BceJ2315_30870 (BceJ2315_30870) CSB-YP453706BXS
CSB-EP453706BXS
CSB-BP453706BXS
CSB-MP453706BXS
CSB-EP453706BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia 2-dehydro-3-deoxyphosphooctonate aldolase (kdsA) CSB-YP453707BXS
CSB-EP453707BXS
CSB-BP453707BXS
CSB-MP453707BXS
CSB-EP453707BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Phosphoribosylformylglycinamidine cyclo-ligase (purM) CSB-YP453708BXS
CSB-EP453708BXS
CSB-BP453708BXS
CSB-MP453708BXS
CSB-EP453708BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Chaperone protein DnaJ (dnaJ) CSB-YP453709BXS
CSB-EP453709BXS
CSB-BP453709BXS
CSB-MP453709BXS
CSB-EP453709BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Putative iron--sulfur cluster insertion protein ErpA (erpA) CSB-YP453710BXS
CSB-EP453710BXS
CSB-BP453710BXS
CSB-MP453710BXS
CSB-EP453710BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Tryptophan synthase alpha chain (trpA) CSB-YP453711BXS
CSB-EP453711BXS
CSB-BP453711BXS
CSB-MP453711BXS
CSB-EP453711BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia UPF0145 protein BceJ2315_57450 (BceJ2315_57450) CSB-YP453712BXS
CSB-EP453712BXS
CSB-BP453712BXS
CSB-MP453712BXS
CSB-EP453712BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Selenide, water dikinase (selD) CSB-YP453713BXS
CSB-EP453713BXS
CSB-BP453713BXS
CSB-MP453713BXS
CSB-EP453713BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia cepacia Exodeoxyribonuclease 7 small subunit (xseB) CSB-YP453714BXS
CSB-EP453714BXS
CSB-BP453714BXS
CSB-MP453714BXS
CSB-EP453714BXS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Negative modulator of initiation of replication (seqA) CSB-YP453715EYZ
CSB-EP453715EYZ
CSB-BP453715EYZ
CSB-MP453715EYZ
CSB-EP453715EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Molybdenum cofactor biosynthesis protein C (moaC) CSB-YP453716EYZ
CSB-EP453716EYZ
CSB-BP453716EYZ
CSB-MP453716EYZ
CSB-EP453716EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 1- (5-phosphoribosyl)-5-[ (5-phosphoribosylamino)methylideneamino] imidazole-4-carboxamide isomerase CSB-YP453717EYZ
CSB-EP453717EYZ
CSB-BP453717EYZ
CSB-MP453717EYZ
CSB-EP453717EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>